Science · No Itch Please

The Science Behind No Itch Please

No Itch Please contains no active pharmaceutical ingredient. There is no antihistamine, no corticosteroid, no local anaesthetic, no menthol, no plant extract and no drug of any kind in this patch. It is a grid-structured adhesive applied over a bite, and everything it does, it does mechanically.

  • 22 References
  • Reviewed 19.08.2026
Contents
  1. 01Introduction
  2. 02Why through the skin
  3. 03Product-specific evidence
  4. 04User survey
  5. 05Safety
  6. 06References
01 — Introduction

What this page covers

That makes this the shortest ingredient list and the longest mechanism section in our range. There is no absorption question to answer, no molecular weight to report and no 500-Dalton rule to apply, because there is no molecule intended to enter the body. What there is instead is a genuinely well-established piece of sensory neuroscience: the observation, formalised by Melzack and Wall in Science in 1965 and repeatedly confirmed in human experiments since, that mechanical stimulation of large-diameter cutaneous afferents suppresses the transmission of itch and pain signals in the dorsal horn of the spinal cord.

The second mechanism is simpler, and arguably the more useful one. A patch physically covers the bite. A covered bite cannot be scratched, and scratching is what turns a small, self-limiting histamine reaction into a larger, longer, more inflamed one.

Below: why a bite itches, how counter-stimulation closes the gate on that signal, why the surface is a grid, and a numbered bibliography of 22 sources with DOI links.

02 — Transdermal evidence

Why through the skin

THERE IS NOTHING TO ABSORB

Most of our patches are designed to move a molecule across the stratum corneum, and their science pages are therefore about molecular weight, lipophilicity and the 500-Dalton rule described by Bos and Meinardi (2000). None of that applies here. No Itch Please carries no active substance. Nothing is intended to cross the skin barrier, so no penetration data are relevant, no plasma pharmacokinetics exist to report, and no drug interaction is possible. This is a mechanical device in the shape of a patch, and that is a design choice, not a shortfall.

WHY A BITE ITCHES

Mosquito saliva is not inert. It contains anticoagulants, vasodilators and a set of characterised salivary allergens. Peng and Simons (1996, 2004, 2007) describe a biphasic cutaneous response: an immediate reaction, appearing within minutes and peaking at around 20 minutes, consisting of a pruritic wheal with a surrounding flare, correlating with mosquito salivary-gland-specific IgE and IgG; and a delayed reaction, an indurated papule appearing hours later, peaking at 24 to 36 hours and correlating with lymphocyte proliferation responses rather than antibody titres. The immediate phase is histaminergic, with histamine coming both from the saliva itself and from IgE-dependent mast cell degranulation.

Histamine binds H1 receptors on peripheral C-fibre nerve endings. Those fibres project to the dorsal horn of the spinal cord, where the itch signal is relayed toward the brain. That relay is where this product acts.

GATE CONTROL: THE 1965 IDEA THAT STILL HOLDS

Melzack and Wall published Pain Mechanisms: A New Theory in Science in 1965. Their proposal was that a mechanism in the dorsal horns acts as a gate that facilitates or inhibits transmission from the periphery to the brain, and that the setting of the gate depends on the relative activity in large- and small-diameter afferent fibres, modulated by descending control from the brain. Activity in large-diameter mechanoreceptive fibres closes the gate on small-fibre input.

This is why rubbing a knock reduces the pain, and it is the theoretical basis for TENS, for vibration therapy and for a very large body of clinical practice. It is one of the most cited papers in the history of pain research.

Itch obeys the same logic. Akiyama, Carstens and Carstens (2011) recorded from superficial dorsal horn neurons in a mouse model of itch. Those neurons showed high spontaneous firing, which was significantly attenuated by scratching, by pinch and by noxious heat. Crucially, they identified the transmitters: the scratch-evoked inhibition was nearly abolished by spinal delivery of the glycine antagonist strychnine and was markedly reduced by GABA antagonists, and it was attenuated by interrupting the upper cervical cord, showing that both segmental and supraspinal circuits are involved. Reviews by Dhand and Aminoff (2014) and by Ma (2012) place this within the broader architecture of itch and pain coding, where interconnected labelled lines allow one modality to inhibit another.

WHAT HUMAN EXPERIMENTS SHOW

The animal electrophysiology is supported by controlled experiments in people.

Ekblom, Fjellner and Hansson (1984) injected histamine intradermally into the upper arm of 12 healthy volunteers to induce itch, then applied mechanical vibration at 10, 100 and 200 Hz and transcutaneous electrical stimulation at 2 and 100 Hz. Vibratory and electrical stimulation at every frequency tested reduced subjective itch intensity. Vibration at 100 Hz was the most effective mode, particularly when applied directly to the itching area, and it also shortened the duration of the itch and reduced the total itch index, with the shortest induction time to partial and maximal relief.

Ward, Wright and McMahon (1996) induced itch by histamine iontophoresis in healthy volunteers, then applied counterstimuli to the skin. Innocuous stimuli produced a 20 to 30 percent reduction in ratings, which the authors attributed largely to distraction. Noxious counterstimuli produced a consistent and significant inhibition of itch of 22.8 to 52.7 percent, and the anti-pruritic effect persisted for more than 30 minutes after the counterstimulus had stopped. That persistence is the finding that matters: an effect which outlasts the stimulus is not simple distraction, and points to a central mechanism.

The direction of this literature is consistent across four decades and multiple stimulus modalities: non-pharmacological mechanical stimulation of the skin reduces itch, and the effect is generated in the central nervous system rather than at the receptor.

WHY A GRID

A flat, smooth patch presses uniformly. A grid-structured surface creates a repeating pattern of raised contact points and gaps, producing localised pressure gradients and a small amount of skin lift between them as the adhesive tensions the surface. Mechanically, that means many discrete points of sustained low-level mechanoreceptor activation across and around the bite rather than one uniform contact, and it means that activation continues for as long as the patch is worn. The grid is a rational engineering application of a demonstrated principle: sustained mechanical input to the skin inhibits itch centrally, so the surface is built to deliver sustained mechanical input.

THE SECOND MECHANISM: YOU CANNOT SCRATCH THROUGH IT

The most reliable thing this patch does is the least sophisticated. It covers the bite.

Scratching gives a few seconds of relief, by exactly the counter-stimulation mechanism described above, at the cost of mechanical damage to the epidermis, further mediator release, and more itch. Reviews of the itch-scratch cycle (Harrison and Spada 2019; Steinhoff et al. 2026; Kwatra 2020) describe this self-reinforcing loop and note that repeated scratching drives inflammation and delays healing.

Broken skin over a bite is also a recognised portal of entry for bacteria, which is why scratching a bite open is worth avoiding in the first place. Bowen et al. (2015), in a systematic review of 89 studies, estimated a median childhood impetigo prevalence of 12.3 percent, with more than 162 million children affected globally at any one time, concentrated in tropical and resource-poor settings.

A patch that keeps fingernails off the lesion, and shields it from friction, addresses the scratching directly. This mechanism requires no theory of neurotransmission at all, and it is why we think this product suits children who cannot be persuaded to leave a bite alone.

03 — Product evidence

What exists for this product itself

No Itch Please rests on three established foundations.

The mechanism science is peer-reviewed and old enough to have become textbook. Melzack and Wall's gate control theory, published in Science in 1965, is one of the most cited papers in the history of pain research, and its specific application to itch has been worked out since. Akiyama, Carstens and Carstens (2011) recorded from superficial dorsal horn neurons in a mouse model of itch and showed that counter-stimulation inhibits itch-signalling neurons through glycine- and GABA-mediated spinal pathways, with both segmental and supraspinal circuits involved. In humans, Ekblom, Fjellner and Hansson (1984) showed that mechanical vibration applied to a histamine-induced itch in 12 healthy volunteers reduced its subjective intensity, shortened its duration and lowered the total itch index. Ward, Wright and McMahon (1996) measured a consistent and significant inhibition of experimentally induced itch of 22.8 to 52.7 percent from noxious counterstimuli, an effect that persisted for more than 30 minutes after the counterstimulus stopped - which places the mechanism in the central nervous system rather than at the receptor.

The approach is established practice. Non-pharmacological counter-stimulation of the skin - vibration, TENS, cutaneous field stimulation - has been in clinical and consumer use for decades on exactly this principle, and it works without a drug, without absorption and without systemic exposure of any kind. No Itch Please applies it with a grid-structured adhesive surface: many discrete points of sustained low-level mechanoreceptor activation across and around the bite, for as long as the patch is worn. Alongside it runs a second mechanism that needs no theory at all - the patch covers the bite, and fingernails cannot reach through it, which is the part of the itch-scratch cycle most worth interrupting (Harrison and Spada 2019; Bowen et al. 2015).

The third foundation is our own work. We are investing in product-specific testing of the finished patch, and results will be published on this page as they arrive.

04 — User data

What our users report

Any figure we publish about how quickly this patch works comes from customer self-report, and itch is unusually difficult to self-report about.

Itch is subjective, it fluctuates spontaneously, and a mosquito bite resolves on its own within hours to days regardless of what is done to it. A person applying a patch and noticing relief a few minutes later cannot separate the patch from the natural time course of a histamine wheal, which typically peaks around 20 minutes and then subsides. This is precisely the situation in which uncontrolled self-report is least reliable, and it is why the experimental literature cited on this page uses standardised itch induction and within-subject controls.

So: where our marketing describes rapid relief, that describes what customers report experiencing. It is not a measured onset time, it is not benchmarked against an untreated control bite, and it should not be read as a clinical finding.

What customer feedback does support, and what we think is the genuinely useful signal, is that the patch stops people, and especially children, from scratching. That is an observable behaviour rather than a sensation, it does not depend on introspection, and it is the mechanism with the clearest link to how a bite actually heals.

Where internal survey figures are used elsewhere in our communication, they come from an unblinded, uncontrolled, self-reported customer questionnaire and are labelled as such.

Internal customer survey. n greater than 500 users, self-reported questionnaire, unblinded and uncontrolled, with no untreated control bite for comparison. Not a randomised controlled trial. Given that mosquito bites resolve spontaneously, self-reported relief cannot be separated from natural resolution in a design of this kind.

05 — Safety

Safety and side effects

FOR EXTERNAL USE ONLY. Apply to clean, dry, intact skin over the bite. Do not reuse a patch.

This product contains no active pharmaceutical ingredient. There is no drug to absorb, no systemic exposure and no known drug interaction.

Do not apply to broken, bleeding, weeping, blistered, already-scratched-open or infected skin. Do not apply to mucous membranes or to the immediate eye area. If the skin under a patch becomes red, sore or itchier than the bite itself, remove it: adhesives can cause contact irritation and, less commonly, allergic contact dermatitis.

CHILDREN: recommended for ages 2 and over, applied and removed by an adult. Small adhesive patches are a choking and ingestion hazard for infants and toddlers. Keep used and unused patches out of reach of children, check the patch periodically while it is worn, and remove it if a child works it loose.

SEEK MEDICAL ADVICE, DO NOT RELY ON THIS PRODUCT, if any of the following occur: spreading redness, warmth, swelling or streaking around the bite; pus, yellow crusting or a sore that will not heal, which can indicate impetigo or cellulitis; fever; a bite that becomes rapidly and severely swollen, painful or blistered; any breathing difficulty, throat tightness, widespread hives, faintness or facial swelling after a bite, which may indicate a systemic allergic reaction and is a medical emergency; or a bite acquired in an area with tick-borne, mosquito-borne or other vector-borne disease, especially if followed by fever, rash or an expanding ring-shaped lesion.

Do not use this product on a tick that is still attached. Ticks must be removed promptly and correctly with fine-tipped tweezers, not covered.

This product does not treat infection, does not treat allergic reactions, and does not substitute for antihistamines, corticosteroids or medical care where those are indicated.

Store below 25 degrees Celsius, away from direct sunlight.

These statements have not been evaluated by the Food and Drug Administration, or by the equivalent authority in the country of sale. This product is not intended to diagnose, treat, cure or prevent any disease.

06 — References

References

GATE CONTROL AND THE SPINAL PROCESSING OF ITCH

COUNTER-STIMULATION IN HUMAN EXPERIMENTS

THERMAL COUNTER-STIMULATION AFTER INSECT BITES

  • [12] Metz M, Elberskirch M, Reuter C, Liedtke L, Maurer M. Efficacy of concentrated heat for treatment of insect bites: a real-world study. Acta Derm Venereol. 2023;103:adv11592.
    https://doi.org/10.2340/actadv.v103.11592

WHY A BITE ITCHES

  • [13] Peng Z, Simons FE. Mosquito allergy: immune mechanisms and recombinant salivary allergens. Int Arch Allergy Immunol. 2004;133(2):198-209.
    https://doi.org/10.1159/000076787
  • [14] Peng Z, Simons FE. Advances in mosquito allergy. Curr Opin Allergy Clin Immunol. 2007;7(4):350-354.
    https://doi.org/10.1097/ACI.0b013e328259c313
  • [15] Peng Z, Yang M, Simons FE. Immunologic mechanisms in mosquito allergy: correlation of skin reactions with specific IgE and IgG antibodies and lymphocyte proliferation response to mosquito antigens. Ann Allergy Asthma Immunol. 1996;77(3):238-244.
    https://doi.org/10.1016/S1081-1206(10)63262-0

THE ITCH-SCRATCH CYCLE AND THE COST OF SCRATCHING

SKIN BARRIER AND ABSORPTION CONTEXT

MOSQUITO BITE CONTEXT

  • [22] McMeniman CJ, Corfas RA, Matthews BJ, Ritchie SA, Vosshall LB. Multimodal integration of carbon dioxide and other sensory cues drives mosquito attraction to humans. Cell. 2014;156(5):1060-1071.
    https://doi.org/10.1016/j.cell.2013.12.044
View No Itch Please

Last reviewed: 19.08.2026 · 22 References